PTGS2 and neoplasm: According to their results, cyclooxygenase-2 (COX-2) and α-smooth muscle actin (α-SMA) were dramatically decreased during therapy and the immunosuppressive microenvironment of the CT26 tumor was also relieved, resulting in the compromised tumor-promoting inflammation.